Rubicon Research Limited (RUBICON) Free Cash Flow 2025–2026

Name: Rubicon Research Limited (RUBICON) free cash flow history 2025-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Rubicon Research Limited annual free cash flow for fiscal 2026 was -₹241 million. All figures are reported results from public filings — no estimates or projections.

RUBICON Annual Free Cash Flow

Free Cash Flow (annual)	2026-03-31	2025-03-31
Free Cash Flow	(₹241M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Free Cash Flow at Comparable Companies

4503 Free Cash Flow — Astellas Pharma Inc.
4528 Free Cash Flow — Ono Pharmaceutical Co., Ltd.
4536 Free Cash Flow — Santen Pharmaceutical Co., Ltd.
GLAXO Free Cash Flow — GlaxoSmithKline Pharmaceuticals Limited
NOVN Free Cash Flow — Novartis AG

More RUBICON metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS

All RUBICON financial statements → Interactive RUBICON charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.